This PubMed record describes a pooled analysis titled “Central Nervous System Activity of Lazertinib in EGFR‑Mutated NSCLC With Prior EGFR TKI Exposure: A Pooled Analysis of KCSG‑LU20‑15 and LU21‑01.” The article is published in Thorac Cancer (2026 Sep;17[17]:e70387). Bibliographic identifiers reported in the record include DOI 10.1111/1759-7714.70387 and PubMed ID (PMID) 42670582.
The title and available metadata indicate the primary focus is the CNS activity of lazertinib in patients with EGFR‑mutated non‑small cell lung cancer (NSCLC) who had prior exposure to EGFR tyrosine kinase inhibitors (TKIs). This suggests the analysis aims to evaluate intracranial efficacy or central nervous system outcomes for lazertinib after earlier EGFR TKI therapy; however, the provided PubMed excerpt does not include the abstract or outcome data.
The analysis pools data from two named clinical efforts: KCSG‑LU20‑15 and LU21‑01. The record confirms the pooled‑analysis design by title but does not provide trial‑level details in the supplied text. Specifically, the PubMed excerpt does not report the following items for either trial: trial phase, study design (prospective vs retrospective), sample size, eligibility criteria, dosing of lazertinib, primary and secondary endpoints, methods for assessing CNS response, duration of follow‑up, or statistical approach to pooling data.
The PubMed record lists a multi‑institutional Korean authorship group led by Dong Hyun Kim with numerous coauthors affiliated to tertiary centers and cancer institutes in the Republic of Korea. Reported institutional affiliations include, among others: Seoul National University Hospital and Cancer Research Institute; Yonsei Cancer Center, Severance Hospital; Samsung Medical Center; Gachon University Gil Medical Center; National Cancer Center; Seoul National University Bundang Hospital; Korea University Anam Hospital; and The Catholic University of Korea (Seoul St Mary’s Hospital). The authorship list and affiliations are provided in full in the source record.
The PubMed entry provides the journal reference (Thorac Cancer, 2026 Sep), DOI 10.1111/1759-7714.70387, and PMID 42670582. These identifiers can be used to locate the full text or official abstract through the journal website, DOI resolver, or PubMed link.
The supplied PubMed content is limited to the title, author list, affiliations, and bibliographic metadata. The following critical items were not present in the provided source text and therefore cannot be restated or interpreted here:
Because these outcomes and methodological details are not included in the PubMed excerpt provided here, any interpretation of efficacy, comparative benefit, or safety would require consulting the full published manuscript.
For clinicians or researchers seeking the complete dataset, results, and formal conclusions, retrieve the full article using the DOI (10.1111/1759-7714.70387) or PMID (42670582) via the publisher’s site (Thorac Cancer) or PubMed. The full text will provide the methods, quantitative CNS efficacy endpoints for lazertinib, safety findings, and the authors’ discussion and conclusions.
Note on this summary
This editorial rewrite preserves the original study focus and bibliographic information from the PubMed record. Specific efficacy and safety findings, trial methodology, numeric outcomes, and authors’ interpretive comments were not present in the provided source text and therefore are explicitly noted as unavailable here. Consult the full published article for the primary data and validated clinical conclusions regarding lazertinib CNS activity in previously EGFR TKI‑treated EGFR‑mutant NSCLC.